The Future Of Allogeneic Cell Therapy: ASC's Hypoimmunogenic Donor Cells
In this insightful webinar presented by Applied StemCell, Founder and CEO Ruby Tsai, Ph.D., explores innovative strategies for developing hypoimmunogenic cells, a critical advancement for the field of allogeneic cell therapies. Dr. Tsai delves into the general methodologies for reducing immunogenicity in cell-based therapeutics and highlights the unique approach employed by Applied StemCell to overcome immune rejection challenges.
Central to this approach are the company’s proprietary technologies, including the TARGATT® gene editing platform and HLA-F technologies, which enable precise genetic modifications to create universal donor cells. By leveraging these cutting-edge tools, Applied StemCell aims to advance the development of scalable, off-the-shelf cell therapies that can benefit a broad range of patients without the need for complex and costly patient-specific customization. This webinar offers valuable insights into the future of allogeneic therapies and the groundbreaking solutions driving their success.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.